California-based clinical-stage biotechnology company Carmot Therapeutics has raised USD 150 million in a Series E funding round led by Deep Track Capital, with participation from new investors 5AM Ventures and Franklin Templeton, as well as existing investors RA Capital Management and Willett Advisors. This brings the total funds raised to USD 384.8 million.
The funds will be used to strengthen Carmot's clinical and preclinical assets for modulating gut hormones involved in energy homeostasis.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.